Investigating how specific mutations in the SF3B1 gene affect cancer development and treatment options.
Harnessing hotspot specific differences among SF3B1 mutations to define novel mechanisms of tumorigenicity and targetability in solid malignancies
This study is looking at how certain changes in a gene called SF3B1, which are often found in cancers like breast cancer and leukemia, affect how tumors grow and behave, with the hope of finding better treatments for patients with these types of cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-10877705 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of SF3B1 mutations, which are commonly found in various cancers, including breast cancer and acute myeloid leukemia. By using innovative genome editing techniques, the study aims to explore how different SF3B1 mutations influence tumor growth and behavior in cell models. The researchers will analyze changes in gene expression and cancer cell characteristics, such as growth and spread, to identify potential new treatment strategies targeting these mutations. This work could lead to improved therapies for patients with cancers driven by SF3B1 mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with breast cancer, melanoma, or acute myeloid leukemia who have SF3B1 mutations.
Not a fit: Patients without SF3B1 mutations or those with cancers not associated with this gene may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with cancers associated with SF3B1 mutations.
How similar studies have performed: Previous research has shown promising results in targeting SF3B1 mutations in acute myeloid leukemia, indicating potential for success in similar approaches for solid tumors.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Bergman, Riley — Vanderbilt University
- Study coordinator: Bergman, Riley
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.